New targets for medical treatment of lipid disorders.

被引:9
作者
Brousseau M.E. [1 ]
Schaefer E.J. [1 ]
机构
[1] JM-USDA-HNRCA at Tufts University, 711 Washington Street, Boston, 02111, MA
关键词
Ezetimibe; Cholesteryl Ester Transfer Protein; Arterioscler Thromb Vasc Biol; Microsomal Triglyceride Transfer Protein; Cholesteryl Ester Transfer Protein Inhibitor;
D O I
10.1007/s11883-002-0071-x
中图分类号
学科分类号
摘要
Coronary heart disease (CHD) is the leading cause of death and disability in the industrialized world. Included among the risk factors for CHD are an elevated level of low-density lipoprotein (LDL) cholesterol and a low level of high-density lipoprotein (HDL) cholesterol. The discovery of drugs that inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase (statins), the rate-limiting enzyme in cholesterol biosynthesis, constituted a major advance in the treatment of patients with elevated plasma concentrations of LDL cholesterol. However, although the statins are potent LDL-lowering agents, they may not be the therapy of choice for all dyslipidemic patients. This is particularly true for subjects whose primary lipid abnormality is a low level of HDL cholesterol with or without hypertriglyceridemia, a group that includes about one half of patients with CHD. In this report, we review emerging options for the treatment of patients with lipid disorders, including inhibitors of cholesterol absorption, acyl coenzyme A-cholesterol acyltransferase, microsomal triglyceride transfer protein, and cholesteryl ester transfer protein, as well as liver X receptor agonists that up-regulate the expression of ATP-binding cassette transporter A1.
引用
收藏
页码:343 / 349
页数:6
相关论文
共 110 条
  • [1] LaRosa JC(1999)Effect of statins on risk of coronary heart disease: a meta-analysis of randomized controlled trials JAMA 282 2340-2346
  • [2] He J(1992)Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein(a) abnormalities in men with premature coronary heart disease J Am Coll Cardiol 19 792-802
  • [3] Vupputuri S(1997)In vivo mechanism-based discovery of a potent cholesterol absorption inhibitor (SCH58235) through the identification of active metabolites of SCH48461 J Pharmacol Exp Ther 283 157-163
  • [4] Genest JJ(1998)Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption J Med Chem 41 973-980
  • [5] McNamara JR(2000)Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663 Br J Pharmacol 129 1748-1754
  • [6] Ordovas JM(2000)Ezetimibe (SCH58235) localizes to the brush border of small intestinal enterocyte and inhibits enterocyte cholesterol uptake and absorption [abstract] Eur Heart J 21 636-636
  • [7] van Heek M(2001)The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys Eur J Pharmacol 415 79-84
  • [8] France CF(2001)The synergistic hypochol-esterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in dogs Metabolism 50 1234-1241
  • [9] Compton DS(2000)The cholesterol absorption inhibitor ezetimibe (SCH58235) and lovastatin synergistically lower plasma cholesterol and inhibit the development of atherosclerosis [abstract] J Am Coll Cardiol 35 255A-2038
  • [10] Rosenblum SB(2001)Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice Arterioscler Thromb Vasc Biol 21 2032-437